November 26, 2024 06:41 AM ESTUpdated 10:10 AM
Deals
Cell/Gene Tx

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Kyle LaHucik

Senior Reporter

Roche is ac­quir­ing its cell ther­a­py and ge­nom­ic med­i­cines part­ner Po­sei­da Ther­a­peu­tics, the com­pa­nies said Tues­day morn­ing.

The Basel-based phar­ma gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Bris­tol My­ers re­veals more job cuts in New Jer­sey

A service from the Financial Times